

Situation-adjusted anticoagulant release can simulate feedback responsive behavior of the blood vessel wall

Manfred F. Maitz, Jan Zitzmann, Jasmin Hanke, Claudia Renneberg, Mikhail V. Tsurkan, Uwe Freudenberg, Carsten Werner

Objective: Healthy vascular endothelium is considered the most effective anti-thrombogenic surface, which can adjust its anticoagulant properties to the actual requirements. Its transmembrane protein thrombomodulin has inherently responsive anticoagulant properties: Only in complex with the activated coagulation factor thrombin it converts Protein C to the anticoagulant Activated Protein C (APC). Activated coagulation thus triggers the formation and release of this anticoagulant. Once formed, the activity of APC is not restricted to the endothelial surface, but interrupts the coagulation process in the fluid phase.

A biohybrid hydrogel of starPEG crosslinked with heparin using thrombin-cleavable linker peptides presents a coagulation responsive anticoagulant system with similar behavior: Thrombin cleaves the linker peptides and releases heparin; this inhibits the thrombin activity and interrupts further degradation of the hydrogel. Since thrombin is a late enzyme in the coagulation cascade, the timing of the heparin release by this trigger may be suboptimal for thromboprotection. Faster degradation by thrombin or by more upstream coagulation factors may provide more efficient anticoagulant hydrogels.

Method: starPEG-Heparin hydrogels were prepared using the previously described thrombin-cleavable peptide, a peptide with faster turn-over, a non-cleavable scrambled sequence of the peptide, a factor FXa cleavable, and a kallikrein/FXIIa cleavable peptide as responsive linkers. They were characterized for their general response behavior and for the performance in whole blood.

Results: At equal concentration of the respective enzymes, the kallikrein responsive hydrogel was degraded fastest, followed by the FXa responsive gel and then the different thrombin responsive gels. In whole blood, the kallikrein-responsive gel also showed best anticoagulation, associated with highest heparin release, what is attributed to the low feedback effect of heparin on the contact phase system. The FXa- and the standard thrombin-responsive hydrogel had equal anticoagulant properties, but the FXa responsive system achieved this with lower heparin release due to the improved timing of the degradation.

Conclusion: Responsive anticoagulant hydrogels responding on FXa as trigger show a favorable profile of thromboresistance and inhibitor release.

Caption

Feedback control of the coagulation cascade: Physiologically, thrombin (FIIa) activates in complex with the vessel wall protein thrombomodulin the Protein C (PC) to the anticoagulant activated PC (aPC) which interrupts the coagulation cascade in the blood. A biosynthetic hydrogel built of the anticoagulant heparin, four-armed poly(ethylene glycol) (starPEG) crosslinked with linker peptides, which can be selectively cleaved by activated coagulation factors can mimic this behavior: FIIa cleaves the linker peptides in the hydrogel and with this releases the anticoagulant heparin to the blood, where it inhibits a several steps of the coagulation cascade in a antithrombin (AT) dependent manner and also terminates further degradation of the hydrogel.